LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company focused on developing differentiated cancer therapies, has announced the engagement of IBN, a multifaceted financial news and publishing company, to support its corporate communications strategy. This partnership aims to leverage IBN's extensive distribution platform, which includes over 5,000 syndication outlets, newsletters, social media channels, blogs, and wire services via InvestorWire, to heighten awareness of LIXTE's first-in-class approach to enhancing the effectiveness of existing chemotherapy and immunotherapy treatments.
Central to LIXTE's pipeline is its lead clinical candidate, LB-100, a first-in-class PP2A inhibitor that has demonstrated tolerability in cancer patients at doses associated with anti-cancer activity. Based on extensive preclinical data published on the company's website (www.lixte.com), LB-100 has the potential to significantly enhance both chemotherapies and immunotherapies, thereby improving outcomes for patients with various cancers. LIXTE is pioneering a new field of cancer biology known as activation lethality, which is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are currently underway for Ovarian Clear Cell Carcinoma and Metastatic Colon Cancer.
The engagement with IBN is expected to amplify LIXTE's messaging to a broader investor audience. IBN's platform, which includes the Dynamic Brand Portfolio, offers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to over 5,000 outlets, enhanced press release distribution, social media reach to millions of followers, and a full array of tailored corporate communications solutions. This collaboration is designed to cut through the information overload in today's market and provide LIXTE with enhanced recognition and brand awareness among investors, influencers, and the general public.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company dedicated to new targets for cancer drug development and the commercialization of cancer therapies. The company's lead compound, LB-100, represents a pioneering effort in activation lethality, advancing a new treatment paradigm. The latest news and updates regarding LIXT are available in the company's newsroom at https://ibn.fm/LIXT.
This strategic move underscores LIXTE's commitment to effectively communicating its scientific advancements and clinical progress to the investment community. By partnering with IBN, LIXTE aims to ensure that its innovative approach to cancer therapy receives the visibility it deserves, potentially attracting further interest and support for its ongoing clinical trials.
